Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

• Status: Active, not recruiting
• Trial end date: 2021-10-01

Summary

This pilot phase I trial studies how well durvalumab given with or without metformin works in treating participants with head and neck squamous cell carcinoma. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread. Metformin, a drug typically used for the treatment of diabetes, may help to reduce the metabolic activity of cancer cells and of surrounding supportive tissues. It is not yet known whether giving durvalumab with or without metformin may work better in treating participants with head and neck squamous carcinoma.

• Phase: Phase 1

Details

• Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
• Treatments: Antibodies, Monoclonal; Durvalumab; Immunoglobulin G; Immunoglobulins; Metformin